Stock Market Today, Oct. 22: Moderna Stock Plummets 18% on Melanoma Vaccine Data Leak Reports

Impact · against what's priced in

Moderna faces a valuation correction as leaked Phase 3 data for its melanoma vaccine (42% risk reduction) underperforms Phase 2 results (49%), undermining the market's bullish pricing of its oncology platform. Peer biotechnology stocks are experiencing sympathetic declines, though the impact is less material for BioNTech given its price largely dismisses oncology upside.

MRNA−0.70

Challenges what's priced in

The price assumes